Real-world Evidence

Omidria Prevents Ifis¹

Patients treated with OMIDRIA had an 84% reduction in observed IFIS symptoms, 79% reduction in iris prolapse, and 90% reduction in severe billowing vs placebo

OMIDRIA inhibits prostaglandin release, thereby reducing inflammation, to maintain iris stability and prevent IFIS.^1,2

Single-center, double-masked, prospective, comparative study (N=50)¹

All patients received the standard preoperative topical mydriatic drops and topical benzocaine on the day of surgery.¹
All patients had conventional phacoemulsification with video recording using an endocyclophotocoagulation (ECP) probe.¹

Learn about lower CME rates

REFERENCES: 1. Silverstein SM, Rana VK, Stephens R, et al. Effect of phenylephrine 1.0%–ketorolac 0.3% injection on tamsulosin-associated intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2018;44(9):1103-1108. 2. Bucci FA Jr, Michalek B, Fluet AT. Comparison of the frequency of use of a pupil expansion device with and without an intracameral phenylephrine and ketorolac injection 1%/0.3% at the time of routine cataract surgery. Clin Ophthalmol. 2017;11:1039-1043.

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

INDICATIONS AND USAGE

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Omidria Prevents Ifis1

Study: Silverstein 2018

Single-center, double-masked, prospective, comparative study (N=50)1

Important Safety Information

Indications and Usage

Click below to Continue or Cancel to stay on this page.

Omidria Prevents Ifis¹

Single-center, double-masked, prospective, comparative study (N=50)¹